Cohance Lifesciences Limited
NSE: COHANCE BSE: COHANCE
NSE
753.40
-25.55 (-3.28%)
Prev Close
778.95
Open Price
779
Volume
1,868,840
Today Low / High
749.05 / 779.45
52 WK Low / High
749.05 / 1123.4
Range
716 - 791
BSE
753.20
-25.50 (-3.27%)
Prev Close
778.7
Open Price
772.65
Volume
53,652
Today Low / High
749 / 778.9
52 WK Low / High
749 / 1359
Range
716 - 791
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 753.4 (target range: 716 - 791), reflecting a change of -25.55 (-3.28006%). On the BSE, it is listed at 753.2 (target range: 716 - 791), showing a change of -25.5 (-3.27469%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
30 Oct
793.00
-1.45%
29 Oct
830.00
-5.25%
28 Oct
858.00
-0.41%
27 Oct
871.65
-2.36%
24 Oct
886.05
-0.99%
23 Oct
893.95
-0.95%
21 Oct
872.20
3.15%
20 Oct
912.30
-3.68%
17 Oct
893.20
-0.24%
16 Oct
875.95
2.52%
15 Oct
867.15
0.22%
14 Oct
884.85
-2.09%
13 Oct
891.75
-0.74%
10 Oct
881.75
2.61%
09 Oct
863.15
2.15%
08 Oct
868.30
-0.85%
07 Oct
869.65
0.62%
06 Oct
873.70
-0.57%
03 Oct
870.50
0.35%
Cohance Lifesciences Limited Graph
Cohance Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Cohance Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 753.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 753.20 | 760.73 | 684.66 - 836.81 |
| 768.26 | 614.61 - 921.92 | ||
| 775.80 | 543.06 - 1,008.53 | ||
| Bearish Scenario | 753.20 | 745.67 | 671.10 - 820.23 |
| 738.14 | 590.51 - 885.76 | ||
| 730.60 | 511.42 - 949.79 |
Overview of Cohance Lifesciences Limited
ISIN
INE03QK01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,285,588
Market Cap
299,052,733,338
Last Dividend
0
Official Website
IPO Date
2020-03-09
DCF Diff
379.56
DCF
407
Financial Ratios Every Investor Needs
Stock Dividend of COHANCE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-09 | September 09, 22 | 5 | 5 | 2022-09-12 | 2022-10-02 | |
| 2022-05-13 | May 13, 22 | 1 | 1 | 2022-05-17 | 2022-06-08 | |
| 2022-02-15 | February 15, 22 | 2 | 2 | 2022-02-16 | 2022-03-10 | |
| 2021-08-13 | August 13, 21 | 1 | 1 | 2021-08-17 | 2021-09-30 | |
| 2021-02-17 | February 17, 21 | 1 | 1 | 2021-02-18 | 2021-03-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,197.58 Cr | 375.72 Cr | 821.86 Cr | 0.6863 | 0.00 Cr | 250.50 Cr | 565.64 Cr | 267.87 Cr | 10.52 | 405.57 Cr | 0.2237 |
| 2024-03-31 | 1,051.35 Cr | 371.64 Cr | 679.71 Cr | 0.6465 | 0.00 Cr | 136.11 Cr | 540.12 Cr | 300.28 Cr | 11.80 | 408.99 Cr | 0.2856 |
| 2023-03-31 | 1,340.33 Cr | 588.22 Cr | 752.11 Cr | 0.5611 | 0.00 Cr | 118.27 Cr | 630.35 Cr | 411.29 Cr | 16.16 | 572.64 Cr | 0.3069 |
| 2022-03-31 | 1,320.22 Cr | 574.11 Cr | 746.11 Cr | 0.5651 | 10.35 Cr | 100.49 Cr | 633.39 Cr | 453.80 Cr | 17.83 | 579.49 Cr | 0.3437 |
| 2021-03-31 | 1,009.72 Cr | 437.18 Cr | 572.54 Cr | 0.5670 | 11.06 Cr | 76.58 Cr | 483.06 Cr | 362.34 Cr | 14.23 | 440.73 Cr | 0.3589 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 85.40 Cr | 3,031.75 Cr | 1,191.11 Cr | 1,696.5800 Cr | 279.07 Cr | 193.67 Cr | 166.57 Cr | 1,250.03 Cr | 0.00 Cr | 0.00 Cr | 144.95 Cr | 365.1900 Cr |
| 2024-03-31 | 47.23 Cr | 2,254.09 Cr | 203.42 Cr | 2,050.6635 Cr | 65.00 Cr | 17.77 Cr | 231.20 Cr | 786.78 Cr | 0.16 Cr | 0.00 Cr | 130.58 Cr | 106.8957 Cr |
| 2023-03-31 | 64.80 Cr | 1,965.74 Cr | 230.56 Cr | 1,735.1843 Cr | 70.34 Cr | 5.54 Cr | 333.29 Cr | 766.22 Cr | 25.57 Cr | 12.86 Cr | 117.10 Cr | 158.7658 Cr |
| 2022-03-31 | 44.56 Cr | 1,829.59 Cr | 302.41 Cr | 1,527.1803 Cr | 97.13 Cr | 52.56 Cr | 301.92 Cr | 561.95 Cr | 3.80 Cr | 37.33 Cr | 117.10 Cr | 210.2940 Cr |
| 2021-03-31 | 7.18 Cr | 1,474.47 Cr | 293.66 Cr | 1,180.8083 Cr | 143.04 Cr | 135.85 Cr | 212.72 Cr | 534.89 Cr | 27.85 Cr | 0.00 Cr | 361.19 Cr | 219.7480 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 288.1600 Cr | -255.3000 Cr | 3.3200 Cr | 132.4500 Cr | 38.3700 Cr | 85.6000 Cr | -155.7100 Cr | 343.9200 Cr | 22.7900 Cr | 0.0000 Cr | 74.1200 Cr |
| 2024-03-31 | 358.4831 Cr | -362.2532 Cr | -13.8023 Cr | 306.6962 Cr | -17.5716 Cr | 47.2312 Cr | -51.7869 Cr | 300.2805 Cr | -6.3512 Cr | 0.0000 Cr | 81.6149 Cr |
| 2023-03-31 | 450.9124 Cr | -194.8422 Cr | -235.8312 Cr | 165.1409 Cr | 20.2390 Cr | 64.8028 Cr | -285.7715 Cr | 559.7298 Cr | -26.3680 Cr | -203.6520 Cr | -29.3932 Cr |
| 2022-03-31 | 330.0002 Cr | -136.2069 Cr | -156.4121 Cr | 254.8135 Cr | 37.3816 Cr | 44.5638 Cr | -75.1867 Cr | 667.5898 Cr | -48.1944 Cr | -101.8260 Cr | -82.3369 Cr |
| 2021-03-31 | 383.4377 Cr | -311.3982 Cr | -76.5529 Cr | 272.5917 Cr | -4.5131 Cr | 7.1822 Cr | -110.8460 Cr | 467.6741 Cr | -41.5336 Cr | -25.4565 Cr | -26.2082 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 549.31 Cr | 148.14 Cr | 401.17 Cr | 0.7303 | 267.85 Cr | 48.88 Cr | 1.91 | 86.24 Cr | 0.0890 |
| 2025-03-31 | 402.02 Cr | 204.43 Cr | 197.59 Cr | 0.4915 | 101.85 Cr | 42.01 Cr | 1.64 | 96.52 Cr | 0.1045 |
| 2024-12-31 | 307.15 Cr | 55.63 Cr | 251.52 Cr | 0.8189 | 188.23 Cr | 82.88 Cr | 3.26 | 110.30 Cr | 0.2698 |
| 2024-09-30 | 257.72 Cr | 52.06 Cr | 205.66 Cr | 0.7980 | 153.79 Cr | 82.21 Cr | 3.23 | 102.23 Cr | 0.3190 |
| 2024-06-30 | 230.69 Cr | 90.68 Cr | 140.01 Cr | 0.6069 | 94.39 Cr | 60.77 Cr | 2.39 | 79.48 Cr | 0.2634 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 280.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,840.64 Cr |
| 2025-03-31 | 85.40 Cr | 205.01 Cr | 290.41 Cr | 284.83 Cr | 166.57 Cr | 888.59 Cr | 1,250.03 Cr | 3,031.75 Cr | 1,191.11 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 655.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,028.42 Cr |
| 2024-09-30 | 36.82 Cr | 619.06 Cr | 655.88 Cr | 185.65 Cr | 215.48 Cr | 1,167.65 Cr | 892.76 Cr | 2,505.56 Cr | 477.14 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 821.13 Cr | 0.00 Cr | 0.00 Cr | 821.13 Cr | 0.00 Cr | 0.00 Cr | -2,050.66 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 48.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 42.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 82.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 82.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 60.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-25 | September 25, 20 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,690.70 | ₹4,056,549,508,373.00 | ₹1,560,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,738.00 | ₹1,788,732,898,056.00 | ₹507,645.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,560.10 | ₹1,204,898,044,500.00 | ₹354,021.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,197.60 | ₹996,839,216,220.00 | ₹4,250,056.00 |
| Mankind Pharma Limited | MANKIND | ₹2,384.00 | ₹984,016,240,160.00 | ₹593,366.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.45 | ₹980,520,395,716.00 | ₹458,971.00 |
| Lupin Limited | LUPIN | ₹1,963.50 | ₹896,844,333,000.00 | ₹1,017,447.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,138.90 | ₹661,474,968,435.00 | ₹3,556,831.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹178,327.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,891.20 | ₹533,698,169,981.00 | ₹398,054.00 |
| Laurus Labs Limited | LAURUSLABS | ₹953.65 | ₹514,804,014,931.00 | ₹1,545,364.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,271.20 | ₹322,508,801,922.00 | ₹106,442.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,465.30 | ₹308,003,793,847.00 | ₹102,941.00 |
| Cohance Lifesciences Limited | COHANCE | ₹753.40 | ₹288,226,083,276.00 | ₹1,868,840.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,682.30 | ₹263,441,852,870.00 | ₹161,890.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,318.90 | ₹250,017,076,708.00 | ₹201,166.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,555.00 | ₹238,875,000,000.00 | ₹20,033.00 |
| Eris Lifesciences Limited | ERIS | ₹1,591.70 | ₹216,811,113,902.00 | ₹40,393.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,473.00 | ₹211,346,761,497.00 | ₹44,604.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,281.50 | ₹208,224,272,482.00 | ₹289,135.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹897.40 | ₹176,395,747,478.00 | ₹69,233.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,101.00 | ₹174,564,413,184.00 | ₹543,954.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,032.80 | ₹154,516,575,629.00 | ₹43,860.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹819.90 | ₹146,852,182,413.00 | ₹412,467.00 |
| Granules India Limited | GRANULES | ₹565.60 | ₹137,253,425,770.00 | ₹384,397.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.45 | ₹110,959,145,199.00 | ₹27,710.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,152.00 | ₹102,119,398,064.00 | ₹17,413.00 |
| Strides Pharma Science Limited | STAR | ₹934.70 | ₹86,153,835,776.00 | ₹9,219,602.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹851.95 | ₹77,214,757,940.00 | ₹105,286.00 |
| FDC Limited | FDC | ₹460.65 | ₹74,998,465,195.00 | ₹252,540.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹460.75 | ₹70,541,773,224.00 | ₹53,334.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹352.85 | ₹69,011,043,776.00 | ₹149,611.00 |
| Sequent Scientific Limited | SEQUENT | ₹214.61 | ₹53,633,796,524.00 | ₹1,034,635.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹465.10 | ₹50,679,744,752.00 | ₹51,856.00 |
| Innova Captab Limited | INNOVACAP | ₹831.10 | ₹47,559,638,492.00 | ₹13,222.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹491.10 | ₹44,822,697,000.00 | ₹54,690.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.19 | ₹43,872,073,482.00 | ₹196,488.00 |
| Suven Life Sciences Limited | SUVEN | ₹197.55 | ₹43,073,939,692.00 | ₹121,404.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,403.90 | ₹39,758,138,159.00 | ₹6,281.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹726.30 | ₹36,837,285,962.00 | ₹86,074.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹470.95 | ₹33,157,587,963.00 | ₹3,282.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹325.40 | ₹32,631,927,452.00 | ₹54,623.00 |
Key Executives
Vice President of Corporate Affairs
Mr. Sunder Venkatraman
Gender: male
Year Born:
Executive Chairman
Mr. Vivek Sharma CPA
Gender: male
Year Born:
Chief Executive Officer
Dr. Sudhir Kumar Singh Ph.D.
Gender: Not Specified
Year Born: 1965
Chief Quality & Compliance Officer
Dr. K. Nagendra Babu Ph.D.
Gender: Not Specified
Year Born:
Chief Financial Officer
Mr. Himanshu Agarwal
Gender: male
Year Born: 1970
Head of Investor Relations
Ms. Cyndrella Carvalho
Gender: female
Year Born:
Chief Human Resources Officer
Mr. Gaurav Narain Bahadur
Gender: male
Year Born: 1970
Chief Commercial Officer
Dr. Declan Ryan Ph.D.
Gender: Not Specified
Year Born:
MD & Director
Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju Ph.D.
Gender: Not Specified
Year Born:
FAQs about Cohance Lifesciences Limited
Who is the CEO of the company?
The CEO is Vivek Sharma.
What is the current market price of the stock?
The current price is ₹781.70.
What is the 52-week price range?
The range is ₹766.8-1123.4.
What is the market capitalization of the company?
The market capitalization is ₹29,905.27 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 118.04.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Cohance Lifesciences Limited (ISIN: INE03QK01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹29,905.27 crores and an average daily volume of 1,285,588 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.